A new treatment for the most common type of motor neurone disease (MND) could improve the neuronal health of sufferers and allow their nervous systems to improve regeneration. Ellorarxine, a novel drug compound developed by Nevrargenics, has demonstrated antioxidant and anti-inflammatory effects, which make it a… Read More
PrecisionLife and the Nucleic Acid Therapy Accelerator (NATA) have announced a collaboration to co-develop novel oligonucleotide therapies for sporadic motor neurone disease/ALS. The collaboration combines NATA’s expertise in NAT design and optimisation with PrecisionLife’s understanding of complex disease biology and the mechanisms, drug targets and treatments… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The news highlights this week are mostly focused around neuroscience, with new guiding principles… Read More
News round-up for 4-8 December by DDW Digital Content Editor Diana Spencer. The news highlights this week are mostly focused around neuroscience, with new guiding principles and a drug repurposing fund launched for motor neuron disease research, a new drug target found for early-onset dementia, and a… Read More
Scientists have identified abnormal aggregates of a protein called TAF15 in the brains of individuals with early-onset dementia, known as frontotemporal dementia, where the cause was not previously known. The research led by scientists from the Medical Research Council (MRC) Laboratory of Molecular Biology, in Cambridge,… Read More
New guidance for the motor neuron disease (MND) drug discovery community has been published to ensure that future drug discovery and development efforts have the best chance of successfully translating from the lab to the clinic. The whitepaper ‘Guiding principles for drug discovery and development in… Read More
A new project by researchers in Edinburgh aims to identify combinations of existing drugs that could be used together to treat motor neuron disease (MND). Led by Prof Siddharthan Chandran, the £3.3 million project is funded by the medical research charity LifeArc, as part of an… Read More
Six UK universities have collectively received £4.25 million as part of a collaborative project aimed at finding new treatments for motor neurone disease (MND). The MND Collaborative Partnership was launched by LifeArc, MND Association, MND Scotland and My Name’5 Doddie Foundation, alongside government bodies Medical Research Council… Read More
Medical research charity LifeArc and the MND Association have established a £1 million joint translational research fund to support researchers developing treatments for Motor Neurone Disease (MND). Despite recent advances, there is still no effective clinical treatment for MND. Each organisation is contributing £500,000 to the fund. Researchers from across… Read More
